---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010748"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:56:26.447128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS licenses ibrexafungerp to GSK for $90M upfront plus up to $503M milestones

## Summary
- Upfront payment of $90M; eligible for up to $70M regulatory, $115M commercial, $242.5M sales, and $75.5M development milestones.
- GSK gets exclusive rights to ibrexafungerp (BREXAFEMME) outside Greater China; SCYNEXIS retains other assets with GSK ROFN.
- SCYNEXIS to repay ~$35.4M loan principal plus fees to Hercules/SVB upon receipt of upfront or by June 1, 2023.
- Transaction expected to close in Q2 2023, subject to HSR waiting period expiration.
- Royalties in mid-single to mid-teen percent on cumulative annual sales.

## SEC filing metadata
- accession: 0000950170-23-010748
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/scyx-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010748
- JSON: https://secwatch.observer/filing/0000950170-23-010748.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010748.txt

## Key facts
- Material Agreements
  SCYNEXIS INC entered into License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) valued at $90 million (effective 2023-03-30).
  - Action: entry
  - Agreement: license
  - Counterparty: GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK)
  - Value: $90 million
  - Effective: 2023-03-30
  source text: On March 30, 2023 SCYNEXIS, Inc. entered into a license agreement (the “License Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm
- Material Agreements
  SCYNEXIS INC amended First Amendment and Consent to Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. valued at approximately $35.4 million.
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A.
  - Value: approximately $35.4 million
  source text: In connection with the entering into of the License Agreement, SCYNEXIS entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to SCYNEXIS entering into the License Agreement and SCYNEXIS agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4 million), (ii) the prepayment fee payable under Loan Agreement ($262,500), (iii) the final payment payable under Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.